Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Reminyl Benefit Seen Among Probable Vascular Dementia Patients

Executive Summary

A study of Janssen's Reminyl (galantamine) showed benefits in patients with probable vascular dementia as well as patients with Alzheimer's disease with cerebrovascular components.
Advertisement

Related Content

Vascular Dementia May Not Be Distinct Clinical Entity, FDA Cmte. Says
Vascular Dementia May Not Be Distinct Clinical Entity, FDA Cmte. Says
Vascular Dementia May Not Be Distinct Clinical Entity, FDA Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS037556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel